255 related articles for article (PubMed ID: 15787812)
1. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis.
Chalmers RJ; Kirby B; Smith A; Burrows P; Little R; Horan M; Hextall JM; Smith CH; Klaber M; Rogers S
Br J Dermatol; 2005 Mar; 152(3):444-50. PubMed ID: 15787812
[TBL] [Abstract][Full Text] [Related]
2. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen.
Maurice PD; Maddox AJ; Green CA; Tatnall F; Schofield JK; Stott DJ
Br J Dermatol; 2005 Mar; 152(3):451-8. PubMed ID: 15787813
[TBL] [Abstract][Full Text] [Related]
3. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients.
Boffa MJ; Smith A; Chalmers RJ; Mitchell DM; Rowan B; Warnes TW; Shomaf M; Haboubi NY
Br J Dermatol; 1996 Oct; 135(4):538-44. PubMed ID: 8915142
[TBL] [Abstract][Full Text] [Related]
4. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.
Lynch M; Higgins E; McCormick PA; Kirby B; Nolan N; Rogers S; Lally A; Vellinga A; Omar H; Collins P
JAMA Dermatol; 2014 Aug; 150(8):856-62. PubMed ID: 24964792
[TBL] [Abstract][Full Text] [Related]
5. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up.
Zachariae H; Heickendorff L; Søgaard H
Br J Dermatol; 2001 Jan; 144(1):100-3. PubMed ID: 11167689
[TBL] [Abstract][Full Text] [Related]
6. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study.
Martyn-Simmons CL; Rosenberg WM; Cross R; Wong T; Smith CH; Barker JN
Br J Dermatol; 2014 Aug; 171(2):267-73. PubMed ID: 24942271
[TBL] [Abstract][Full Text] [Related]
7. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients.
vanDooren-Greebe RJ; Kuijpers AL; Buijs WC; Kniest PH; Corstens FH; Nagengast FM; de Boo T; Willems JL; Duller P; van de Kerkhof PC
Br J Dermatol; 1996 Mar; 134(3):481-7. PubMed ID: 8731673
[TBL] [Abstract][Full Text] [Related]
8. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy.
Lindsay K; Fraser AD; Layton A; Goodfield M; Gruss H; Gough A
Rheumatology (Oxford); 2009 May; 48(5):569-72. PubMed ID: 19273538
[TBL] [Abstract][Full Text] [Related]
9. Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics.
Zachariae H; Søgaard H; Heickendorff L
Acta Derm Venereol; 1989; 69(3):241-4. PubMed ID: 2566230
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients.
van Swelm RP; Laarakkers CM; Kooijmans-Otero M; de Jong EM; Masereeuw R; Russel FG
Toxicol Lett; 2013 Aug; 221(3):219-24. PubMed ID: 23830989
[TBL] [Abstract][Full Text] [Related]
11. Use of amino terminal type III procollagen peptide (P3NP) assay in methotrexate therapy for psoriasis.
Khan S; Subedi D; Chowdhury MM
Postgrad Med J; 2006 May; 82(967):353-4. PubMed ID: 16679477
[TBL] [Abstract][Full Text] [Related]
12. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic.
Barker J; Horn EJ; Lebwohl M; Warren RB; Nast A; Rosenberg W; Smith C;
J Eur Acad Dermatol Venereol; 2011 Jul; 25(7):758-64. PubMed ID: 21198946
[TBL] [Abstract][Full Text] [Related]
13. Liver biopsies and methotrexate: a time for reconsideration?
Zachariae H
J Am Acad Dermatol; 2000 Mar; 42(3):531-4. PubMed ID: 10688735
[No Abstract] [Full Text] [Related]
14. Abnormalities of serum type III procollagen aminoterminal peptide in methotrexate-treated psoriatic patients with normal liver histology do not correlate with hepatic ultrastructural changes.
Oogarah PK; Rowland PL; Mitchell DM; Smith A; Chalmers RJ; Rowan B; Haboubi NY
Br J Dermatol; 1995 Oct; 133(4):512-8. PubMed ID: 7577576
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies--a further 10-year follow-up.
Zachariae H; Søgaard H; Heickendorff L
Dermatology; 1996; 192(4):343-6. PubMed ID: 8864370
[TBL] [Abstract][Full Text] [Related]
16. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary?
Thomas JA; Aithal GP
Am J Clin Dermatol; 2005; 6(6):357-63. PubMed ID: 16343024
[TBL] [Abstract][Full Text] [Related]
17. Daily practice assessment of liver injury in patients with psoriasis on methotrexate.
Driessen RJ; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2010 Jan; 162(1):211-3. PubMed ID: 19903179
[No Abstract] [Full Text] [Related]
18. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent.
Berends MA; Snoek J; de Jong EM; van de Kerkhof PC; van Oijen MG; van Krieken JH; Drenth JP
Aliment Pharmacol Ther; 2006 Sep; 24(5):805-11. PubMed ID: 16918884
[TBL] [Abstract][Full Text] [Related]
19. Comment on: Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy.
Boffa MJ; Smith A; Chalmers RJ
Rheumatology (Oxford); 2009 Nov; 48(11):1464; author reply 1465. PubMed ID: 19671697
[No Abstract] [Full Text] [Related]
20. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis.
Zachariae H; Aslam HM; Bjerring P; Søgaard H; Zachariae E; Heickendorff L
J Am Acad Dermatol; 1991 Jul; 25(1 Pt 1):50-3. PubMed ID: 1880254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
